This meeting took place in 2016

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (X1)

Organizer(s) A. Karolina Palucka, Hyam I. Levitsky and Laurence Zitvogel
March 6—10, 2016
Fairmont Chateau Whistler • Whistler, British Columbia Canada
Discounted Abstract Deadline: Nov 5, 2015
Abstract Deadline: Dec 8, 2015
Scholarship Deadline: Nov 5, 2015
Discounted Registration Deadline: Jan 7, 2016

Sponsored by Regeneron Pharmaceuticals, Inc.

Joint Meeting: Antibodies as Drugs (X2)

Summary of Meeting:
The past decade has seen tremendous developments in novel cancer therapies, through targeting of tumor cell-intrinsic pathways whose activity is linked to genetic alterations, as well as the targeting of tumor cell-extrinsic factors such as growth factors. Remarkable clinical success of checkpoint inhibitors as well as adoptively transferred genetically engineered T cells further demonstrates the critical role of T cells in cancer control and rejection. However, many patients still do not respond to checkpoint inhibitor therapies, possibly due to the lack of T cell repertoire with specificity against cancer antigens. This creates the need for effective means of expanding the T cells in patients via immunization, i.e., cancer vaccines. Much progress has been made in recent years in this regard, and several phase III clinical trials testing various approaches to therapeutic vaccination are ongoing. The challenge for next-generation vaccines is to resolve the discrepancy between the immune and clinical efficacy measured by the rate of cancer rejection. The future immunotherapy of cancer lies in combination approaches targeting T cells as well as cancer genes to combat underlying inflammation. Spectacular progress has been made in these two parallel fields, i.e., cancer genomics and genetics, and tumor immunology. It is time now to link these fields to enable the linking of genetic alterations with the type of immune response. The meeting will therefore host cancer geneticists, cancer biologists, experts in cancer antigen presentation, tumor immunologists and vaccinologists. It will discuss the immunological basis for therapeutic cancer vaccines and how the current understanding of cancer genomics, antigen presentation and T cell biology might enable development of next-generation curative therapies for patients with cancer.

View Meeting Program


Keystone Symposia Future of Science Fund Scholarship Recipients

Dixon Dorand
Case Western Reserve University, USA

Brian J. Francica
Aduro Biotech, USA

Naveen Mehta
Massachusetts Institute of Technology, USA